Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Chi-Med OK'd for China Use of Fruquintinib, its First Drug Approval

publication date: Sep 5, 2018

Hutchison China MediTech (Chi-Med) reported its lead candidate, Elunate® (fruquintinib), was approved in China for third-line use as a metastatic colorectal cancer treatment. Chi-Med said Elunate is the first China-discovered and developed drug approved for an oncology indication following a clinical trial. Chi-Med partners the China rights to Elunate with Lilly, which will be responsible for marketing the drug. The approval triggered a $13.6 million milestone payment from Lilly to Chi-Med. More details....

Stock Symbols: (AIM/NSDQ: HCM) (NYSE: LLY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.